Hologic Inc. (NASDAQ: HOLX) completed its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, the company announced. The deal establishes Hologic as a private company and includes minority investments from a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC.

Stockholders will receive $76 per share in cash plus a non-tradable contingent value right to receive up to $3 per share in two payments of up to $1.50 each. The contingent payments depend on achieving certain global revenue goals for Hologic's Breast Health business in fiscal years 2026 and 2027.

José Almeida was appointed as Chief Executive Officer, effective immediately. Almeida previously served as Chairman, President and CEO of Baxter International Inc. from 2016 to early 2025. He succeeds Stephen MacMillan, who retired after more than 12 years leading the organization.

The transaction was announced on October 21, 2025, and approved by Hologic stockholders on February 5, 2026. Hologic's common stock has ceased trading and will be delisted from the Nasdaq Stock Market.

Before joining Baxter, Almeida served as Chairman, President and CEO of Covidien plc until its acquisition by Medtronic in 2015. He previously held senior leadership roles at Tyco Healthcare and executive positions at Wilson Greatbatch Technologies, Acufex Microsurgical and Codman & Shurtleff, a division of Johnson & Johnson.